Evolent Health (EVH)
(Delayed Data from NYSE)
$8.77 USD
-0.18 (-2.01%)
Updated Sep 29, 2025 04:00 PM ET
After-Market: $8.76 -0.01 (-0.11%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EVH 8.77 -0.18(-2.01%)
Will EVH be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for EVH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EVH
CVS vs. EVH: Which Value-Based Care Stock Deserves Investor Attention?
Evolent Health (EVH) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
EVH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Evolent Health (EVH) Reports Q2 Loss, Misses Revenue Estimates
iRhythm Technologies (IRTC) Reports Q2 Loss, Tops Revenue Estimates
Earnings Preview: Evolent Health (EVH) Q2 Earnings Expected to Decline
Other News for EVH
Evolent Health’s Strategic Exit and Profitability Boost Underpin Buy Rating
Technical picture remains unchanged for EVH after it rises 0.34% on September 26
EVH forms MACD Bullish Signal Line Cross on September 25
Evolent Health (EVH) Gets a Buy from Needham
EVH Crossed Above 20 Day Moving Average on September 24